These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 18176661)

  • 41. The design and synthesis of a tricyclic single-nitrogen scaffold that serves as a 5-HT2C receptor agonist.
    Huck BR; Llamas L; Robarge MJ; Dent TC; Song J; Hodnick WF; Crumrine C; Stricker-Krongrad A; Harrington J; Brunden KR; Bennani YL
    Bioorg Med Chem Lett; 2006 Aug; 16(15):4130-4. PubMed ID: 16750364
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Role of dorsal raphe nucleus 5-HT(1A) and 5-HT(2) receptors in tonic immobility modulation in guinea pigs.
    Ferreira MD; Menescal-de-Oliveira L
    Brain Res; 2009 Aug; 1285():69-76. PubMed ID: 19538947
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Pharmacological, but not genetic, disruptions in 5-HT(2C) receptor function attenuate LPS anorexia in mice.
    Asarian L; Kopf BS; Geary N; Langhans W
    Pharmacol Biochem Behav; 2007 Mar; 86(3):493-8. PubMed ID: 17307246
    [TBL] [Abstract][Full Text] [Related]  

  • 44. 5-HT2C receptor agonists with potential anorectic activity.
    Yoon G; Jeong HJ; Kim JJ; Cheon SH
    Arch Pharm Res; 2008 Aug; 31(8):989-94. PubMed ID: 18787786
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Effects of acute intra-cerebral administration of the 5-HT(2A/C) receptor ligands DOI and ketanserin on impulse control in rats.
    Hadamitzky M; Koch M
    Behav Brain Res; 2009 Dec; 204(1):88-92. PubMed ID: 19467270
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Discovery of a novel azepine series of potent and selective 5-HT2C agonists as potential treatments for urinary incontinence.
    Brennan PE; Whitlock GA; Ho DK; Conlon K; McMurray G
    Bioorg Med Chem Lett; 2009 Sep; 19(17):4999-5003. PubMed ID: 19646865
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Serotonergic receptors in therapeutic approaches to gastrointestinal disorders.
    Neal KB; Bornstein JC
    Curr Opin Pharmacol; 2006 Dec; 6(6):547-52. PubMed ID: 16973419
    [TBL] [Abstract][Full Text] [Related]  

  • 48. 5-HT(7) receptors in the modulation of cognitive processes.
    Cifariello A; Pompili A; Gasbarri A
    Behav Brain Res; 2008 Dec; 195(1):171-9. PubMed ID: 18243350
    [TBL] [Abstract][Full Text] [Related]  

  • 49. 5-HT2C receptor modulators: a patent survey.
    Lee J; Jung ME; Lee J
    Expert Opin Ther Pat; 2010 Nov; 20(11):1429-55. PubMed ID: 20849206
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Serotonin control of central dopaminergic function: focus on in vivo microdialysis studies.
    Di Matteo V; Di Giovanni G; Pierucci M; Esposito E
    Prog Brain Res; 2008; 172():7-44. PubMed ID: 18772026
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Identification of novel serotonin 2C receptor ligands by sequential virtual screening.
    Ahmed A; Choo H; Cho YS; Park WK; Pae AN
    Bioorg Med Chem; 2009 Jul; 17(13):4559-68. PubMed ID: 19464901
    [TBL] [Abstract][Full Text] [Related]  

  • 52. [New pharmacological approaches to the treatment of schizophrenia].
    Uzbay IT
    Turk Psikiyatri Derg; 2009; 20(2):175-82. PubMed ID: 19504368
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Antagonism of serotonergic 5-HT2A/2C receptors: mutual improvement of sleep, cognition and mood?
    Landolt HP; Wehrle R
    Eur J Neurosci; 2009 May; 29(9):1795-809. PubMed ID: 19473234
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Role of spinal 5-HT2 receptor subtypes in quipazine-induced hindlimb movements after a low-thoracic spinal cord transection.
    Ung RV; Landry ES; Rouleau P; Lapointe NP; Rouillard C; Guertin PA
    Eur J Neurosci; 2008 Dec; 28(11):2231-42. PubMed ID: 19019202
    [TBL] [Abstract][Full Text] [Related]  

  • 55. 7-Sulfonamido-3-benzazepines as potent and selective 5-HT2C receptor agonists: hit-to-lead optimization.
    Fish PV; Brown AD; Evrard E; Roberts LR
    Bioorg Med Chem Lett; 2009 Apr; 19(7):1871-5. PubMed ID: 19269173
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Therapeutic potential of 5-HT2C receptor ligands.
    Jensen NH; Cremers TI; Sotty F
    ScientificWorldJournal; 2010 Sep; 10():1870-85. PubMed ID: 20852829
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Pharmacologic modification of serotonergic function: drugs for the study and treatment of psychiatric and other disorders.
    Fuller RW
    J Clin Psychiatry; 1986 Apr; 47 Suppl():4-8. PubMed ID: 3514585
    [TBL] [Abstract][Full Text] [Related]  

  • 58. A-to-I editing of the 5HT2C receptor and behaviour.
    Gardiner K; Du Y
    Brief Funct Genomic Proteomic; 2006 Mar; 5(1):37-42. PubMed ID: 16769676
    [TBL] [Abstract][Full Text] [Related]  

  • 59. The 5-HT(2C) receptor agonist WAY-163909 decreases impulsivity in the 5-choice serial reaction time test.
    Navarra R; Comery TA; Graf R; Rosenzweig-Lipson S; Day M
    Behav Brain Res; 2008 Apr; 188(2):412-5. PubMed ID: 18191235
    [TBL] [Abstract][Full Text] [Related]  

  • 60. RNA editing of the serotonin 5HT2C receptor and its effects on cell signalling, pharmacology and brain function.
    Werry TD; Loiacono R; Sexton PM; Christopoulos A
    Pharmacol Ther; 2008 Jul; 119(1):7-23. PubMed ID: 18554725
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.